ZA971279B - Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors - Google Patents

Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors

Info

Publication number
ZA971279B
ZA971279B ZA971279A ZA971279A ZA971279B ZA 971279 B ZA971279 B ZA 971279B ZA 971279 A ZA971279 A ZA 971279A ZA 971279 A ZA971279 A ZA 971279A ZA 971279 B ZA971279 B ZA 971279B
Authority
ZA
South Africa
Prior art keywords
receptor antagonists
serotonin reuptake
overcoming
inhinitors
pct
Prior art date
Application number
ZA971279A
Inventor
Ann Louise Gabrielle Meulemans
Jean-Paul Rene Marie A Bosmans
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA971279B publication Critical patent/ZA971279B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PCT No. PCT/EP97/00586 Sec. 371 Date Aug. 11, 1998 Sec. 102(e) Date Aug. 11, 1998 PCT Filed Feb. 7, 1997 PCT Pub. No. WO97/29739 PCT Pub. Date Aug. 21, 1997The present invention concerns the use of receptor antagonists of the 5HT4 receptor for avoiding, alleviating, suppressing or overcoming the gastrointestinal side-effects of serotonin reuptake inhibitors. The present invention also concerns pharmaceutical formulations comprising 5HT4-receptor antagonists for alleviating, suppressing or overcoming the gastrointestinal side-effects of serotonin reuptake inhibitors, as well as pharmaceutical compositions comprising 5HT4 receptor antagonists and serotonin reuptake inhibitors.
ZA971279A 1996-02-15 1997-02-14 Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors ZA971279B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96200380 1996-02-15

Publications (1)

Publication Number Publication Date
ZA971279B true ZA971279B (en) 1998-08-14

Family

ID=8223676

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA971279A ZA971279B (en) 1996-02-15 1997-02-14 Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors

Country Status (11)

Country Link
US (1) US5990159A (en)
EP (1) EP0977558B1 (en)
JP (1) JP2000516198A (en)
KR (1) KR100469029B1 (en)
AT (1) ATE250931T1 (en)
AU (1) AU1767997A (en)
CA (1) CA2237582C (en)
DE (1) DE69725345T2 (en)
ES (1) ES2208870T3 (en)
WO (1) WO1997029739A2 (en)
ZA (1) ZA971279B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
WO2000025790A1 (en) * 1998-11-02 2000-05-11 Alza Corporation Controlled delivery of antidepressants
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
FR2846559B1 (en) * 2002-10-31 2007-06-15 Centre Nat Rech Scient PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF A PATHOLOGY RELATED TO OBSESSIVE DRIVING
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
KR20050094843A (en) * 2003-01-13 2005-09-28 다이노젠 파마세우티컬스, 인코포레이티드 Method of treating nausea, vomiting, retching or any combination thereof
ES2528669T3 (en) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
PE20090700A1 (en) 2007-03-29 2009-07-13 Progenics Pharm Inc HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR
MX2009010550A (en) 2007-03-29 2009-12-14 Progenics Pharm Inc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
PT2139890E (en) 2007-03-29 2014-09-03 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
IT1392333B1 (en) * 2008-12-16 2012-02-28 Giofarma S R L PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF DEPRESSIVE PATHOLOGIES, CONTAINING A PROTEIN WITH HIGH TRIPTOFAN / LNAA REPORT
US20190030039A1 (en) * 2016-01-21 2019-01-31 The Trustees Of Columbia University In The City Of New York Prevention of ssri-induced gastrointestinal dysfunction with a 5-ht4 receptor antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000103A1 (en) * 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
GB9316195D0 (en) * 1993-08-05 1993-09-22 Smithkline Beecham Plc Pharmaceuticals
AU4350493A (en) * 1992-06-27 1994-01-24 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
EP0977558B1 (en) 2003-10-01
DE69725345D1 (en) 2003-11-06
WO1997029739A3 (en) 1999-10-28
ES2208870T3 (en) 2004-06-16
CA2237582C (en) 2009-04-14
DE69725345T2 (en) 2004-08-19
AU1767997A (en) 1997-09-02
KR19990067698A (en) 1999-08-25
US5990159A (en) 1999-11-23
EP0977558A2 (en) 2000-02-09
CA2237582A1 (en) 1997-08-21
JP2000516198A (en) 2000-12-05
WO1997029739A2 (en) 1997-08-21
KR100469029B1 (en) 2005-05-27
ATE250931T1 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
ZA971279B (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
MX9702865A (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-idoles as estrogenic agents.
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
YU80902A (en) Indolin-2-one derivateves, preparation and their use as ocytocin receptor ligands
NO995887L (en) Pharmaceutical compositions containing eletripanhemisulfate and caffeine
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
ZA965235B (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
AP9801269A0 (en) Prostaglandin agonists.
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
UA50808C2 (en) Composition for treatment of irds and ards
EP1244452A4 (en) Urotensin-ii receptor antagonists
AU8361198A (en) Novel compounds
BG105277A (en) Prevention of migraine recurrence
CY2039B1 (en) 5-HT 1-like receptor agonist for rectal administration
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
BG102661A (en) Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors
ES2159260A1 (en) Novel composition of paroxetine methanesulfonate
BG102229A (en) Endothelium receptor antagonists
ATE141248T1 (en) NEW BIS-PHENYL WITCHES
AU3267097A (en) Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use
CA2203078A1 (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents